[go: up one dir, main page]

MX2012001313A - Compuesto espirociclicos que contienen nitrogeno y su uso medicinal. - Google Patents

Compuesto espirociclicos que contienen nitrogeno y su uso medicinal.

Info

Publication number
MX2012001313A
MX2012001313A MX2012001313A MX2012001313A MX2012001313A MX 2012001313 A MX2012001313 A MX 2012001313A MX 2012001313 A MX2012001313 A MX 2012001313A MX 2012001313 A MX2012001313 A MX 2012001313A MX 2012001313 A MX2012001313 A MX 2012001313A
Authority
MX
Mexico
Prior art keywords
sup
same
integer
medicinal use
nitrogen
Prior art date
Application number
MX2012001313A
Other languages
English (en)
Inventor
Satoru Noji
Makoto Shiozaki
Masafumi Inoue
Tomoya Miura
Yoshinori Hara
Hiroshi Yamanaka
Katsuya Maeda
Akimi Hori
Yasunori Hase
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012001313(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2012001313A publication Critical patent/MX2012001313A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de la siguiente fórmula general [I]: (ver fórmula (I)) en donde cada símbolo tiene el mismo significado que el definido en la presente o una de sus sales o solvatos farmacéuticamente aceptables y un uso farmacéutico de él en el tratamiento de rechazo de trasplante de órganos, reacción de injerto versus huésped después de trasplante, enfermedad autoinmune, enfermedad alérgica y enfermedad mieloproliferativa crónica.
MX2012001313A 2009-07-31 2010-07-30 Compuesto espirociclicos que contienen nitrogeno y su uso medicinal. MX2012001313A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009179502 2009-07-31
US27413709P 2009-08-13 2009-08-13
PCT/JP2010/062873 WO2011013785A1 (ja) 2009-07-31 2010-07-30 含窒素スピロ環化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
MX2012001313A true MX2012001313A (es) 2012-02-29

Family

ID=43529436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001313A MX2012001313A (es) 2009-07-31 2010-07-30 Compuesto espirociclicos que contienen nitrogeno y su uso medicinal.

Country Status (36)

Country Link
US (4) US8609647B2 (es)
EP (3) EP3181570A1 (es)
JP (9) JP5520158B2 (es)
KR (1) KR101773208B1 (es)
CN (1) CN102510865B (es)
AR (1) AR077497A1 (es)
AU (1) AU2010278066B2 (es)
BR (1) BR112012002157B1 (es)
CA (1) CA2767899C (es)
CO (1) CO6491052A2 (es)
CY (1) CY1118747T1 (es)
DK (1) DK2460806T3 (es)
ES (1) ES2616705T3 (es)
FI (1) FIC20250012I1 (es)
FR (1) FR25C1010I1 (es)
HR (1) HRP20170447T1 (es)
HU (2) HUE033070T2 (es)
IL (1) IL217048A (es)
LT (2) LT2460806T (es)
ME (1) ME02667B (es)
MX (1) MX2012001313A (es)
MY (1) MY163495A (es)
NL (1) NL301321I2 (es)
NO (1) NO2025014I1 (es)
NZ (1) NZ597994A (es)
PE (1) PE20121276A1 (es)
PL (1) PL2460806T3 (es)
PT (1) PT2460806T (es)
RS (1) RS55913B1 (es)
RU (1) RU2630694C2 (es)
SG (1) SG176918A1 (es)
SI (1) SI2460806T1 (es)
SM (1) SMT201700166T1 (es)
TW (1) TWI466885B (es)
WO (1) WO2011013785A1 (es)
ZA (1) ZA201200689B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
KR101541086B1 (ko) * 2010-08-20 2015-08-03 허치슨 메디파르마 리미티드 피롤로피리미딘 화합물 및 그 용도
ES2617339T3 (es) 2010-12-16 2017-06-16 Calchan Limited Derivados de pirrolopirimidina inhibidores de ASK1
BR112014014325B1 (pt) 2011-12-21 2022-06-07 Jiangsu Hengrui Medicine Co.,Ltd. Derivados de pirrol do tipo anel heteroarílico de seis membros, seus usos e seus processos de preparação, e composição farmacêutica
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
MY176525A (en) 2013-10-21 2020-08-13 Japan Tobacco Inc Therapeutic agent for ocular disease or prophylactic agent for ocular disease
RU2674027C2 (ru) * 2014-05-28 2018-12-04 Астразенека Аб Способ получения AZD5363 (варианты) и применяемое в нем новое промежуточное соединение
TWI729990B (zh) * 2015-07-07 2021-06-11 日商日本煙草產業股份有限公司 7H-吡咯并[2,3-d]嘧啶衍生物的製造方法及其中間物
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
RU2754997C2 (ru) * 2015-09-24 2021-09-08 Лео Фарма А/С Лечение очаговой алопеции
EP3353168B1 (en) * 2015-09-25 2023-08-30 Dizal (Jiangsu) Pharmaceutical Co., Limited Compounds and methods for inhibiting jak
BR112018014769A2 (pt) 2016-01-21 2018-12-11 Leo Pharma A/S ?composto, composição farmacêutica, e, método para tratamento do eczema nas mãos?
MX388786B (es) 2016-08-01 2025-03-20 Aptinyx Inc Moduladores nmda espiro-lactam y métodos de uso de los mismos.
EP3543241B8 (en) * 2016-11-23 2022-10-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for and intermediate of pyrrolo six-membered heteroaromatic ring derivative
BR112019012210A2 (pt) * 2016-12-21 2019-11-12 Japan Tobacco Inc formas cristalinas de um inibidor de janus cinase
JP6359791B1 (ja) * 2016-12-21 2018-07-18 日本たばこ産業株式会社 ７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体の製造方法及びその共結晶
KR102546513B1 (ko) * 2016-12-21 2023-06-23 니뽄 다바코 산교 가부시키가이샤 7H-피롤로[2,3-d]피리미딘 유도체의 제조 방법 및 그의 합성 중간체
US10851116B2 (en) 2017-01-20 2020-12-01 Leo Pharma A/S Bicyclic amines as novel JAK kinase inhibitors
CN110248663A (zh) * 2017-02-03 2019-09-17 利奥制药有限公司 作为新型JAK激酶抑制剂的5-(7H-吡咯并[2,3-d]嘧啶-4-基)-5-氮杂螺[2.5]辛烷-8-甲酸衍生物
SG11202002707VA (en) * 2017-10-10 2020-04-29 Biogen Inc Process for preparing spiro derivatives
CA3089559A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2021528479A (ja) * 2018-07-06 2021-10-21 レオ ファーマ アクティーゼルスカブ ヤヌスキナーゼ阻害剤としての新規アミノ−イミダゾピリミジン誘導体およびその製薬学的用途
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
EP3968997A1 (en) 2019-05-15 2022-03-23 Leo Pharma A/S Treatment of cutaneous lupus erythematosus
KR20220044288A (ko) * 2019-08-07 2022-04-07 로토 세이야쿠 가부시키가이샤 누액 분비 촉진용 안과 조성물
EP4674401A2 (en) * 2019-12-27 2026-01-07 Rohto Pharmaceutical Co., Ltd Container accommodating an aqueous ophthalmic composition comprising delgocitinib
CN111574540B (zh) * 2020-06-30 2023-08-29 云南华派医药科技有限公司 一种德高替尼的制备方法
CN111560021B (zh) * 2020-06-30 2023-05-26 上海鲲博玖瑞医药科技发展有限公司 一种德高替尼中间体及其制备方法
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
TW202227452A (zh) * 2020-12-04 2022-07-16 大陸商廣州費米子科技有限責任公司 氮雜並環化合物、其製備方法、抑制酪氨酸激酶的方法、藥物組成物及其用途
WO2022143629A1 (zh) * 2020-12-29 2022-07-07 上海岸阔医药科技有限公司 治疗与抗肿瘤剂相关的皮肤疾病或病症的试剂和方法
US20250275974A1 (en) 2022-04-20 2025-09-04 Leo Pharma A/S Treatment of frontal fibrosing alopecia
WO2024180493A1 (en) 2023-02-28 2024-09-06 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
AU2024238918A1 (en) 2023-03-17 2025-10-09 Leo Pharma A/S A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema
WO2024225445A1 (en) 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib
WO2025085050A1 (en) * 2023-10-16 2025-04-24 Leo Pharma A/S Treatment of frontal fibrosing alopecia

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA00011889A (es) 1998-06-02 2003-04-25 Osi Pharm Inc Composiciones de pirrolo (2,3d) piridina y su uso.
AU3951899A (en) * 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
ATE380031T1 (de) 1999-12-10 2007-12-15 Pfizer Prod Inc Pyrrolo 2,3-d pyrimidinderivate enthaltende zusammensetzungen
EP1519939B9 (en) * 2002-07-05 2011-04-06 Targacept, Inc. N-aryl diazaspirocyclic compounds and methods of preparation and use thereof
WO2005047286A1 (ja) 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. スピロ複素環化合物
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CA2598956A1 (en) 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
US8921376B2 (en) * 2005-05-20 2014-12-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
EP3838903B1 (en) 2005-12-13 2023-11-22 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2008029237A2 (en) 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis
JP2010513385A (ja) 2006-12-22 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー スピロ−ピペリジン誘導体
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
PE20090996A1 (es) * 2007-04-02 2009-07-15 Palau Pharma Sa Derivados de pirrolopirimidina como inhibidores de cinasa jak3
WO2009047255A1 (en) * 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
CN102015708B (zh) 2008-01-09 2014-03-26 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
WO2010003133A2 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
JP2018028525A (ja) * 2016-08-15 2018-02-22 小野　信行 イオンレーザーと重水素を利用した核融合炉
JP6229778B2 (ja) * 2016-09-21 2017-11-15 サミー株式会社 遊技機

Also Published As

Publication number Publication date
JP2016029104A (ja) 2016-03-03
US20110136778A1 (en) 2011-06-09
AU2010278066B2 (en) 2016-04-14
JP2021183653A (ja) 2021-12-02
EP3858349A1 (en) 2021-08-04
JP2018111701A (ja) 2018-07-19
JP2011046700A (ja) 2011-03-10
JP2023138641A (ja) 2023-10-02
ES2616705T3 (es) 2017-06-14
HUS2500013I1 (hu) 2025-03-28
EP2460806A4 (en) 2012-12-26
WO2011013785A1 (ja) 2011-02-03
CA2767899A1 (en) 2011-02-03
US20140187534A1 (en) 2014-07-03
LTPA2025511I1 (es) 2025-03-25
SMT201700166T1 (it) 2017-05-08
TWI466885B (zh) 2015-01-01
MY163495A (en) 2017-09-15
TW201107325A (en) 2011-03-01
JP2014141516A (ja) 2014-08-07
SI2460806T1 (sl) 2017-04-26
PT2460806T (pt) 2017-02-27
BR112012002157B1 (pt) 2022-02-08
CY1118747T1 (el) 2017-07-12
KR101773208B1 (ko) 2017-08-31
RU2012106344A (ru) 2013-08-27
RU2630694C2 (ru) 2017-09-12
US8609647B2 (en) 2013-12-17
DK2460806T3 (en) 2017-03-20
CA2767899C (en) 2018-08-28
ZA201200689B (en) 2012-10-31
JP2025109780A (ja) 2025-07-25
JP2017019877A (ja) 2017-01-26
FR25C1010I1 (fr) 2025-04-25
HRP20170447T1 (hr) 2017-05-19
PE20121276A1 (es) 2012-09-27
RS55913B1 (sr) 2017-09-29
US20240150367A1 (en) 2024-05-09
CN102510865B (zh) 2015-04-15
SG176918A1 (en) 2012-01-30
NZ597994A (en) 2013-08-30
AR077497A1 (es) 2011-08-31
EP2460806A1 (en) 2012-06-06
JP5520158B2 (ja) 2014-06-11
ME02667B (me) 2017-06-20
EP2460806B1 (en) 2017-01-04
AU2010278066A1 (en) 2012-03-01
BR112012002157A2 (pt) 2020-08-18
JP2020033384A (ja) 2020-03-05
KR20120051649A (ko) 2012-05-22
FIC20250012I1 (fi) 2025-02-28
US20230023377A1 (en) 2023-01-26
EP3181570A1 (en) 2017-06-21
IL217048A (en) 2014-12-31
LT2460806T (lt) 2017-02-10
NL301321I2 (nl) 2025-07-17
CN102510865A (zh) 2012-06-20
CO6491052A2 (es) 2012-07-31
HUE033070T2 (hu) 2017-11-28
NO2025014I1 (no) 2025-03-04
IL217048A0 (en) 2012-02-29
PL2460806T3 (pl) 2017-06-30

Similar Documents

Publication Publication Date Title
MX2012001313A (es) Compuesto espirociclicos que contienen nitrogeno y su uso medicinal.
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
PH12012501021A1 (en) Indole compound and pharmaceutical use thereof
MY177250A (en) Novel nicotinamide derivative or salt thereof
MX2010008101A (es) Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un silanilo, su preparacion y su aplicacion en terapeutica.
MX2014006366A (es) Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
TN2015000121A1 (en) Gdf-8 inhibitors
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
TW201204363A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
WO2009115517A3 (en) Pyridines and pyrazines as inhibitors of pi3k
IN2012DN03182A (es)
EA201290520A1 (ru) Производные дифенилпиразолопиридинов, их получение и применение в качестве модуляторов нуклеарного рецептора not
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
MX2012012421A (es) Compuestos tetrahidrobenzotiofena.
MX338551B (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
MX2011013648A (es) Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
MY151072A (en) Heteroaryl derivative
NZ718514A (en) Compounds, compositions and methods useful for cholesterol mobilisation
PH12015502429A1 (en) Dicarboxylic acid compound
MX2013006420A (es) Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
MX2018006225A (es) Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.

Legal Events

Date Code Title Description
FG Grant or registration